TY - JOUR
T1 - Neoadjuvant chemotherapy for lymph node-positive penile cancer
T2 - Current evidence and knowledge
AU - Bandini, Marco
AU - Pederzoli, Filippo
AU - Necchi, Andrea
N1 - Publisher Copyright:
© 2020 Wolters Kluwer Health, Inc. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Purpose of reviewTo review the latest in penile cancer treatment focusing on neoadjuvant chemotherapy in patients with regional lymph node involvement.Recent findingsPatients with regional lymph node involvement from penile cancer still suffer from a poor prognosis, and the chances to achieve cure are primarily dependent on the extent of the disease. Despite multiple lines of research are indicating the need for a multimodal management of the disease upfront, the search for newer effective systemic therapies is ongoing. The available guidelines currently suggest the use of combination chemotherapy regimens including taxanes and cisplatin as induction therapy before lymphadenectomy in patients with locally advanced disease (i.e., fixed or bulky inguinal lymph nodes or pelvic lymph node involvement). Research in the field will aim to provide more effective systemic therapies also in patients with a more limited disease spread to further improve the outcomes. Data from the literature also indicate the possibility to effectively administer postoperative chemotherapy in selected high-risk patients.SummaryWe aimed to provide the evidence from the literature and the new avenues that would help delineating the optimal therapeutic pathway for these complex patients, commenting on the new opportunities that may come from the ongoing research.
AB - Purpose of reviewTo review the latest in penile cancer treatment focusing on neoadjuvant chemotherapy in patients with regional lymph node involvement.Recent findingsPatients with regional lymph node involvement from penile cancer still suffer from a poor prognosis, and the chances to achieve cure are primarily dependent on the extent of the disease. Despite multiple lines of research are indicating the need for a multimodal management of the disease upfront, the search for newer effective systemic therapies is ongoing. The available guidelines currently suggest the use of combination chemotherapy regimens including taxanes and cisplatin as induction therapy before lymphadenectomy in patients with locally advanced disease (i.e., fixed or bulky inguinal lymph nodes or pelvic lymph node involvement). Research in the field will aim to provide more effective systemic therapies also in patients with a more limited disease spread to further improve the outcomes. Data from the literature also indicate the possibility to effectively administer postoperative chemotherapy in selected high-risk patients.SummaryWe aimed to provide the evidence from the literature and the new avenues that would help delineating the optimal therapeutic pathway for these complex patients, commenting on the new opportunities that may come from the ongoing research.
KW - lymphadenectomy
KW - neoadjuvant chemotherapy
KW - penile cancer
KW - squamous cell carcinoma
KW - systemic therapies
UR - http://www.scopus.com/inward/record.url?scp=85081150725&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081150725&partnerID=8YFLogxK
U2 - 10.1097/MOU.0000000000000719
DO - 10.1097/MOU.0000000000000719
M3 - Review article
C2 - 31913205
AN - SCOPUS:85081150725
VL - 30
SP - 218
EP - 222
JO - Current Opinion in Urology
JF - Current Opinion in Urology
SN - 0963-0643
IS - 2
ER -